Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
| Autor: | Brit Mollenhauer, Ben P M Geurtz, Anouke van Rumund, Rejko Krüger, Rianne A. J. Esselink, Lukas Pavelka, Marcel M. Verbeek, Bastiaan R. Bloem, Ron A. Wevers |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Levodopa Parkinson's disease Neurology [D14] [Human health sciences] Decarboxylase inhibitor Pharmacology Article 03 medical and health sciences Cellular and Molecular Neuroscience All institutes and research themes of the Radboud University Medical Center 0302 clinical medicine Peripheral decarboxylase inhibitors (PDIs) Dopamine Medicine levodopa RC346-429 chemistry.chemical_classification Aromatic L-amino acid decarboxylase Neurologie [D14] [Sciences de la santé humaine] biology business.industry Parkinsonism Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] medicine.disease Enzyme assay Enzymes nervous system diseases 3. Good health 030104 developmental biology Enzyme Neurology chemistry biology.protein Neurology. Diseases of the nervous system Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | NPJ Parkinson's Disease NPJ Parkinson's Disease, 7 npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-5 (2021) NPJ Parkinson's Disease, 7, 1 |
| ISSN: | 2373-8057 |
| Popis: | Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed in many patients with Parkinson’s disease. We evaluated the effect of levodopa/PDI use on serum AADC enzyme activity. Serum AADC enzyme activity was evaluated in three independent cohorts of patients with Parkinson’s disease or parkinsonism (n = 301) and compared between patients on levodopa/PDI vs. patients not on this medication. AADC enzyme activity was elevated in 62% of patients on levodopa/PDI treatment, compared to 19% of patients not on levodopa/PDI (median 90 mU/L vs. 50 mU/L, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|